News Novo says Wegovy shot works in childhood obesity Novo has published the results of a trial of its Wegovy injection in children aged six to 12 with obesity, showing the drug reduced their BMI.
News Lilly beats Novo to China with an oral GLP-1 for obesity Lilly's orforglipron has been approved in China, becoming the first oral GLP-1 agonist to enter the Chinese weight management market.
News Oral Wegovy bolsters Novo in Q3 Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy.
News Judge backs Lilly in Novo lawsuit over weight-loss drug ads A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.
News UK watchdog takes first action on oral weight drug adverts Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.
News New diabetes and obesity studies making waves at EASD As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.